We have engineered a DNA epitope vaccine that expresses 3 self-B cell epitopes of Aβ 42 (3Aβ 1-11 ), a non-self T helper (Th) cell epitope (PADRE), and 3 copies of C3d (3C3d), a component of complement as a molecular adjuvant, designed to safely reduce CNS Aβ. Immunization of mice with 3Aβ 1-11 -PADRE epitope vaccine alone generated only moderate levels of anti-Aβ antibodies and a pro-inflammatory T helper (Th1 phenotype) cellular immune response. However, the addition of 3C3d to the vaccine construct significantly augmented the anti-Aβ humoral immune response and, importantly, shifted the cellular immune response towards the potentially safer anti-inflammatory Th2 phenotype.
Introduction
One of the major health concerns for elderly people is Alzheimer's disease (AD), which is the most common form of dementia with progressive loss of memory and general cognitive decline. The first immunotherapy clinical trial on Alzheimer's patients, AN-1792, was halted when a subset of those immunized with the vaccine containing the amyloid-beta peptide (Aβ 42 ) developed adverse events (aseptic meningoencephalitis) in the central nervous system (CNS) (Orgogozo et al., 2003; Schenk, 2002; Steinberg, 2002) . While the actual cause of the adverse events is unknown, speculation has centered on autoreactive T cells specific for the T cell epitope in Aβ, the conventional adjuvant (QS21), and the reformulation of the vaccine with polysorbate 80 during the phase IIa portion of the trial (Ferrer et al., 2004; Nicoll et al., 2003; Schenk, 2002) . Subsequent analysis of postmortem brain tissue from patients that received the AN-1792 vaccine showed an overall reduction of Aβ burden in the CNS (Boche et al., 2007; Ferrer et al., 2004; Holmes et al., 2008; Masliah et al., 2005; Nicoll et al., 2006; Nicoll et al., 2003; Nitsch and Hock, 2007; Patton et al., 2006) , and some suggestion of diminished progressive cognitive decline associated with the disease (Gilman et al., 2005; Hock et al., 2003) , although this observation was not universal (Holmes et al., 2008) . However, there was also evidence of increased CNS Aβ by ELISA (Patton et al., 2006) , and increased incidence of cerebral vascular Aβ deposition (Holmes et al., 2008; Masliah et al., 2005; Nicoll et al., 2006; Patton et al., 2006) . In the elderly AD patients, there were a low percentage of responders and the generally low titers in response to a self-Aβ antigen in the AN-1792 vaccine, even in the presence of a very potent adjuvant (Gilman et al., 2005; Patton et al., 2006) . These results emphasize the difficulty facing active immunization approaches in elderly AD patients because the elderly generally develop functional deficits in their immune system or immunosenescence (Grubeck-Loebenstein and Wick, 2002) . Accordingly, to avoid the problems associated with active immunization of elderly AD patients, recent clinical trials based on passive vaccination (AAB-001) were initiated. In these studies, different concentrations of humanized monoclonal anti-Aβ antibody are passively transferred to AD patients. However, passive immunotherapy requires the repeated administration of high doses of expensive humanized monoclonal anti-Aβ antibody. More importantly, this strategy is not likely to be useful for protective vaccination due to the substantial cost, invasive nature of Journal of Neuroimmunology 205 (2008) 57-63 
